NAMD
Clinical trials for NAMD explained in plain language.
Never miss a new study
Get alerted when new NAMD trials appear
Sign up with your email to follow new studies for NAMD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye drug shows promise for blinding disease
Disease control Recruiting nowThis study tests a new medicine called SCT520FF for people with wet age-related macular degeneration (nAMD), a condition that can cause vision loss. The trial will include 82 adults aged 45 to 80 to check the drug's safety and how well it works. The goal is to control the disease…
Matched conditions: NAMD
Phase: PHASE1, PHASE2 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated May 17, 2026 03:00 UTC
-
One-Shot gene therapy could end frequent eye injections for wet AMD
Disease control Recruiting nowThis study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it can control the disease as well as standard treatments that require eye injections every few months. About 714 adults a…
Matched conditions: NAMD
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Eye implant could replace monthly shots for wet AMD
Disease control Recruiting nowThis study tests a small implant placed in the eye that releases medication every 24 weeks, compared to standard monthly eye injections. It involves 68 Chinese patients with wet age-related macular degeneration who have already responded to treatment. The goal is to see if the im…
Matched conditions: NAMD
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC